Fig. 4

MPTP-induced inflammation was reduced in the serum, liver, and BMDM from mice injected with LV3-siNlrp3. a Blots of NLRP3 activation signaling markers in the liver samples from the LV3-NC or the LV3-siNlrp3 mice 7 days post MPTP treatment. b Analysis with the indicated antibodies (n = 4 animals per condition). Data is presented as mean ± SEM, two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001 versus the corresponding saline group; ^#p < 0.05, ^##p < 0.01 versus corresponding LV3-NC group. c, d The secretion of caspase-1, TNF-α, IL-β, IL-12, and IL-18 to serum were determined via ELISA (n = 8 animals per condition). Data is presented as mean ± SEM, two-way ANOVA, **p < 0.01, ***p < 0.001 versus the corresponding saline group; ^#p < 0.05, ^##p < 0.01 versus the corresponding LV3-NC group). e, f Representative blots and analysis of NLRP3 activation signaling makers in the BMDM samples from the LV3-NC or the LV3-siNlrp3 mice 7 days post MPTP treatment (n = 4 animals per condition). Samples were collected after 7 days of last MPTP injection. Data is presented as mean ± SEM, two-way ANOVA,*p < 0.05, **p < 0.01, ***p < 0.001 versus the corresponding saline group; ^#p < 0.05, ^##p < 0.01 versus the corresponding LV3-NC group